Fluidigm Corporation (NASDAQ:FLDM) insider Levin Capital Strategies, L.P. acquired 95,843 shares of the company’s stock in a transaction that occurred on Tuesday, October 10th. The stock was acquired at an average price of $4.57 per share, with a total value of $438,002.51. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Levin Capital Strategies, L.P. also recently made the following trade(s):

  • On Monday, October 9th, Levin Capital Strategies, L.P. acquired 50,000 shares of Fluidigm Corporation stock. The stock was acquired at an average price of $4.59 per share, with a total value of $229,500.00.
  • On Tuesday, September 12th, Levin Capital Strategies, L.P. acquired 60,000 shares of Fluidigm Corporation stock. The stock was acquired at an average price of $5.25 per share, with a total value of $315,000.00.
  • On Thursday, August 17th, Levin Capital Strategies, L.P. acquired 465 shares of Fluidigm Corporation stock. The stock was acquired at an average price of $3.66 per share, with a total value of $1,701.90.
  • On Thursday, August 10th, Levin Capital Strategies, L.P. acquired 4,003,129 shares of Fluidigm Corporation stock. The stock was acquired at an average price of $3.30 per share, with a total value of $13,210,325.70.
  • On Wednesday, August 9th, Levin Capital Strategies, L.P. purchased 1,549 shares of Fluidigm Corporation stock. The shares were purchased at an average price of $3.18 per share, with a total value of $4,925.82.

Fluidigm Corporation (NASDAQ:FLDM) traded up 0.87% on Wednesday, reaching $4.62. 148,645 shares of the company’s stock traded hands. The firm’s market capitalization is $135.89 million. Fluidigm Corporation has a 52 week low of $2.52 and a 52 week high of $8.69. The stock has a 50-day moving average of $4.84 and a 200 day moving average of $4.53.

Fluidigm Corporation (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.02. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The firm had revenue of $23.90 million for the quarter, compared to analyst estimates of $23.50 million. During the same quarter last year, the firm posted ($0.63) earnings per share. Fluidigm Corporation’s revenue for the quarter was down 15.2% compared to the same quarter last year. On average, equities analysts expect that Fluidigm Corporation will post ($2.08) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Fluidigm Corporation (FLDM) Insider Acquires 95,843 Shares of Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/insider-buying-fluidigm-corporation-fldm-insider-acquires-95843-shares-of-stock.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. American International Group Inc. raised its stake in shares of Fluidigm Corporation by 7.1% during the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock valued at $102,000 after purchasing an additional 1,187 shares during the period. Wells Fargo & Company MN raised its stake in shares of Fluidigm Corporation by 15.0% during the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock valued at $146,000 after purchasing an additional 3,327 shares during the period. Virtu KCG Holdings LLC purchased a new stake in shares of Fluidigm Corporation during the second quarter valued at approximately $105,000. PDT Partners LLC raised its stake in shares of Fluidigm Corporation by 56.0% during the second quarter. PDT Partners LLC now owns 27,300 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 9,800 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of Fluidigm Corporation by 18.4% during the second quarter. Alliancebernstein L.P. now owns 45,700 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 7,100 shares during the period. Institutional investors own 88.85% of the company’s stock.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.